表紙
市場調查報告書

嵌合抗原受體表現T細胞(CAR-T細胞)療法的全球市場:2018年∼2022年

Global CAR T-cell Therapy Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 718255
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
嵌合抗原受體表現T細胞(CAR-T細胞)療法的全球市場:2018年∼2022年 Global CAR T-cell Therapy Market 2018-2022
出版日期: 2018年09月24日內容資訊: 英文 112 Pages
簡介

關於CAR-T細胞療法

嵌合抗原受體(CAR)通常在腫瘤學領域是製藥工業中用於治療嚴重威脅生命的疾病的最新創新之一。CAR是工程受體,可攻擊癌細胞。在該療法中,患者的T細胞被修飾以攻擊癌細胞。在該療法中,患者的T細胞在實驗室中被修改以對抗各種癌症適應症。

Technavio的分析師預測,從2018年到2022年,全球CAR-T細胞療法市場將以63.15%的年複合成長率成長。

本報告提供全球CAR-T細胞療法市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017年∼2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 開發平台

第8章 市場區隔:各抗原

  • 市場區隔:各抗原(2017年∼2022年)
  • 比較:各抗原
  • CD19
  • CD22
  • 其他
  • 市場機會:各抗原

第9章 客戶形勢

第10章 地區形勢

  • 各地區市場區隔(2017年∼2022年)
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 主要國家
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 協調性的研究開發努力
  • 退還補償
  • 裝甲CAR-T細胞的出現

第14章 業者情勢

  • 概要
  • 創造性破壞狀況

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis

第16章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR23888

About CAR T-cell Therapy

Chimeric antigen receptor (CAR) is one of the recent innovations in the pharmaceutical industry for the treatment of serious, life-threatening diseases, typically in the areas of oncology. CARs are engineered receptors to attack cancer cells. In this therapy, patients' T-cells are modified to attack cancer cells. In this therapy, patients' T-cells are modified in the laboratory to fight against various cancer indications.

Technavio's analysts forecast the Global CAR T-cell Therapy Market to grow at a CAGR of 63.15% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the CAR T-cell therapy market. To calculate the market size, the report considers the revenue generated from the application of CAR T-cell therapy across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, CAR T-cell Therapy Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis

Market driver

  • Proven effectiveness of CAR T-cell therapy
  • For a full, detailed list, view our report

Market challenge

  • High cost of CAR T-cell therapy
  • For a full, detailed list, view our report

Market trend

  • Collaborative R&D efforts
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY ANTIGEN

  • Segmentation by antigen
  • Comparison by antigen
  • CD19 - Market size and forecast 2017-2022
  • CD22 - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by antigen

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Collaborative R&D efforts
  • Reimbursement coverage
  • Advent of armored CAR T-cells

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market: Global regenerative medicines market
  • Exhibit 02: Global regenerative medicines market segmentation
  • Exhibit 03: Market characteristics: Overview
  • Exhibit 04: Market segments
  • Exhibit 05: CAR T-cell therapy process
  • Exhibit 06: CAR T-cell therapy - Market overview
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2017
  • Exhibit 09: Validation techniques employed for market sizing 2017
  • Exhibit 10: Global CAR T-cell therapy market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 11: Global CAR T-cell therapy market - Year-over-year growth 2018-2022 (%)
  • Exhibit 12: Five forces analysis 2017
  • Exhibit 13: Five forces analysis 2022
  • Exhibit 14: Bargaining power of buyers
  • Exhibit 15: Bargaining power of suppliers
  • Exhibit 16: Threat of new entrants
  • Exhibit 17: Threat of substitutes
  • Exhibit 18: Threat of rivalry
  • Exhibit 19: Market condition - Five forces 2017
  • Exhibit 20: Major indications covered under CAR T-cell therapy R&D landscape
  • Exhibit 21: Global CAR T-cell therapy market pipeline: Overview
  • Exhibit 22: CAR T-cell therapy pipeline: Overview
  • Exhibit 23: Global CAR T-cell therapy market - Market share by antigen 2017-2022 (%)
  • Exhibit 24: Comparison by antigen
  • Exhibit 25: Global CAR T-cell therapy market by CD19 - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Global CAR T-cell therapy market by CD19 - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Global CAR T-cell therapy market by CD22 - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 28: Global CAR T-cell therapy market by CD22 - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Global CAR T-cell therapy market by others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Other antigens: Overview
  • Exhibit 31: Global CAR T-cell therapy market by others - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Market opportunity by antigen
  • Exhibit 33: Customer landscape
  • Exhibit 34: Global CAR T-cell therapy - Market share by geography 2017-2022 (%)
  • Exhibit 35: Regional comparison
  • Exhibit 36: CAR T-cell therapy market in Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 37: CAR T-cell therapy market in Americas - Overview
  • Exhibit 38: CAR T-cell therapy market in Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: CAR T-cell therapy market in EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 40: CAR T-cell therapy market in EMEA - Overview
  • Exhibit 41: CAR T-cell therapy market in EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: CAR T-cell therapy market in APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 43: CAR T-cell therapy market in APAC - Overview
  • Exhibit 44: CAR T-cell therapy market in APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 45: Key leading countries: Overview
  • Exhibit 46: Market opportunity
  • Exhibit 47: Segmentation of therapies in research based on tumor type
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered: Overview
  • Exhibit 51: Vendor classification: Overview
  • Exhibit 52: Market positioning of vendors: Overview
  • Exhibit 53: bluebird bio - Overview
  • Exhibit 54: bluebird bio - Business segments
  • Exhibit 55: bluebird bio - Organizational developments
  • Exhibit 56: bluebird bio - Key offerings
  • Exhibit 57: bluebird bio - Key customers
  • Exhibit 58: CARsgen Therapeutics - Overview
  • Exhibit 59: CARsgen Therapeutics - Business segments
  • Exhibit 60: CARsgen Therapeutics - Organizational developments
  • Exhibit 61: CARsgen Therapeutics - Key offerings
  • Exhibit 62: CARsgen Therapeutics - Key customers
  • Exhibit 63: Celgene - Overview
  • Exhibit 64: Celgene - Business segments
  • Exhibit 65: Celgene - Organizational developments
  • Exhibit 66: Celgene - Geographic focus
  • Exhibit 67: Celgene - Key offerings
  • Exhibit 68: Celgene - Key customers
  • Exhibit 69: Gilead - Overview
  • Exhibit 70: Gilead - Business segments
  • Exhibit 71: Gilead - Organizational developments
  • Exhibit 72: Gilead - Geographic focus
  • Exhibit 73: Gilead - Key offerings
  • Exhibit 74: Gilead - Key customers
  • Exhibit 75: Novartis - Overview
  • Exhibit 76: Novartis - Business segments
  • Exhibit 77: Novartis - Organizational developments
  • Exhibit 78: Novartis - Geographic focus
  • Exhibit 79: Novartis - Segment focus
  • Exhibit 80: Novartis - Key offerings
  • Exhibit 81: Novartis - Key customers